Tratamiento de trombocitopenia inmune primaria con eltrombopag en un paciente con síndrome coronario agudo reciente

Bermejo, Nuria; Sigüenza, Raúl; Ibáñez, Fátima.
Rev. esp. cardiol. (Ed. impr.) ; 70(1): 56-57, ene. 2017.
Artículo en Español | IBECS (España) | ID: ibc-159309

Documentos relacionados

  1. Patient-tailored antithrombotic therapy following percutaneous coronary intervention.
  2. Is There a Role for Triple Therapy After ACS?
  3. [Adherence of patients with atrial fibrillation after acute coronary syndrome to antithrombotic therapy at stage III of cardiac rehabilitation: data from the local register of the Kirov region].
  4. Dual pathway therapy in acute coronary syndrome.
  5. Antithrombotic Therapy after Acute Coronary Syndromes. Reply.
  6. Antithrombotic Therapy after Acute Coronary Syndromes.
  7. Antithrombotic Therapy after Acute Coronary Syndromes.
  8. Optimisation of antithrombotic therapy in patients with acute coronary syndrome to reduce bleeding episodes.
  9. [Anticoagulation status and adherence in patients with atrial fibrillation hospitalized for ACS and the impact on 1-year prognosis: a multicenter cohort study].
  10. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum.